REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Six-membered Consisting Of Two Nitrogens And Four Carbon Atoms (e.g., Pyridazines, Etc.) > 1,4-diazine As One Of The Cyclos > Piperazines (i.e., Fully Hydrogenated 1,4-diazines) Piperazines (i.e., Fully Hydrogenated 1,4-diazines)Piperazines (i.e., Fully Hydrogenated 1,4-diazines) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/25/07 - 20070021434 - Non-nucleoside anti-hepacivirus agents and uses thereof The present dislcosure provides amide-based, non-nucleoside compounds having antiviral activity against Hepacivirus, such as hepatitis C virus (HCV), methods and intermediates for synthesizing such compounds, and methods of using the compounds in a variety of contexts, including in the treatment and prevention of viral infections. The present dislcosure also provides ... 01/04/07 - 20070004743 - Intranasal administration of mc4-r agonists A method for delivering a melanocortin-4 receptor agonist to a mammalian subject, includes administering the melanocortin-4 receptor agonist to a tissue inside the nasal cavity or sinuses of the mammalian subject. In some instances, the melanocortin-4 receptor agonist includes a guanidine functional group. ... 12/21/06 - 20060287332 - Melanocortin receptor-specific piperazine and keto-piperazine compounds and pharmaceutically acceptable salts thereof, where X, W, J, Q, L1, L2, L3, R1a, R1b, R2a, and R2b are as defined in the specification, and the carbon atom marked with an asterisk can have any stereochemical configuration. Compounds disclosed herein bind to one or more melanocortin receptors and may be ... 12/21/06 - 20060287331 - Melanocortin receptor-specific piperazine compounds with diamine groups and pharmaceutically acceptable salts thereof, where W is a diamine heteroatom unit with at least one cationic center, hydrogen bond donor or hydrogen bond acceptor, J, Q, L1, L2, L3, R1a, R1b, R2a, R2b and X are as defined in the specification, and the carbon atom marked with an asterisk ... 12/07/06 - 20060276479 - Heterocyclic substituted piperazines with cxcr3 antagonist activity or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting ... 11/02/06 - 20060247248 - Sigma-1 receptor ligand with acetylcholinesterase A novel compound and method for preventing or treating neurodegenerative diseases by inhibiting acetylcholinesterase and binding the sigma-1 receptor are disclosed. Dimethylcarbamic acid 2,3-bis-dimethylcarbamoyloxy-6-[4-(4-ethyl-piperazin-yl)-butyryl]-phenyl ester and its derivatives represent a novel therapeutic strategy against β-amyloid peptide induced neurotoxicity, in inhibiting acetylcholinesterase, in improving cholinergic transmission, in binding the sigma-1 receptor, ... 08/17/06 - 20060183748 - Identification of compounds that inhibit replication of human immunodeficiency virus The present invention relates to the discovery of a novel class of compounds that inhibit the replication of human immunodeficiency virus (HIV) and approaches to identify these compounds. More specifically, it has been found that enzymatically prepared alpha-hydroxyglycinamide and synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum. ... 07/27/06 - 20060167003 - Probucol derivatives Probucol derivatives and pharmaceutical compositions containing the same to be employed in treatment or prophylaxis of diseases. ... 07/06/06 - 20060148811 - Aralkyl-ketone piperazine derivatives and their uses as new antalgic or ataractic agent and pharmaceutical compositions comprising the same. Also dislcosed are methods for using the compounds as analgesic and sedative agents. The compounds of the present invention have good analgesic and sedative activities but few side effects. ... 05/25/06 - 20060111361 - Method of reversing left ventricle remodeling The present invention relates to method of reversing left ventricle remodeling by combined administration of therapeutically effective amounts ranolazine and at least one co-remodeling agent, which may be an ACE inhibitor, an ARB, or a beta-blocker. The method finds utility in the treatment of heart failure. This invention also relates ... 05/25/06 - 20060111360 - Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders wherein V, W, Y, Z, R1, R2, R3, R4, d, m, n, p and r are herein defined, said compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as ... 03/30/06 - 20060069100 - Variously substituted derivatives of guanidine, and their use as medicines with anti-diabetes and/or anti-obesity activity Formula (I) compounds are described where the groups are as identified in the text, and their use as medicines, particularly as anti-diabetes, serum glucose-lowering and anti-obesity agents. Said medicines are useful for the prophylaxis and treatment of diabetes, particularly type 2 diabetes, and its complications, syndrome X, the various forms ... 03/09/06 - 20060052386 - Sigma ligands for neuronal regeneration and functional recovery The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferably AGY-94806, or salts, or solvates thereof. These molecules can be delivered alone or in combination with agents which ... 01/19/06 - 20060014753 - Sigma ligands for neuronal regeneration and functional recovery The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferably AGY-94806, or salts, or solvates thereof. These molecules can be delivered alone or in combination with agents which ... 01/12/06 - 20060009462 - Prodrugs of cc-1065 analogs Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in which the prodrug also has a moiety, such as a ... 12/15/05 - 20050277647 - Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other ... 12/01/05 - 20050267121 - Aralkyl-alcohol peiperazine derivatives adn their uses as antidepressant and pharmaceutical compositions comprising the same. Also disclosed are methods for treating depression using the pharmaceutical compositon. Compounds of the invention have excellent dual inhibitory actions to the uptake of the mono-amines neurotransmitter, good antidepressant activities and minor side effects. ... 11/24/05 - 20050261302 - Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme and their therapeutic application The present invention relates to the use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment or prophylactically treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic ... 11/03/05 - 20050245535 - Sulfonyl amide inhibitors of calcium channel function its stereoisomers, solvates, and salts, thereof, wherein: a, b, c, d, f, n, m and Ra are defined herein are are inhibitors of calcium channel function, and are useful in treating calcium channel-dependent disorders, including hypertension. ... 11/03/05 - 20050245534 - Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other ... 11/03/05 - 20050245533 - Inhibitors of the 11-beta-hydroxysteroid dehydrogenasetype 1 enzyme and their therapeutic application The present invention relates to the use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment or prophylactically treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic ... 11/03/05 - 20050245532 - Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme and their therapeutic application The present invention relates to the use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment or prophylactically treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic ... 10/13/05 - 20050227990 - Aminoalkoxy-functional chalcones The invention provides novel alkoxyaminochalcone derivatives and analogues thereof. Use of the compounds, or compositions comprising them, as pharmaceutically active agents, in particular against bacterial and parasitic infections, is also disclosed. The invention further relates to a method for detecting inhibitory effects against e.g., bacteria, parasites, fungi, and helminths. The ... 09/29/05 - 20050215562 - Methods for treating protein aggregation disorders The present invention is based, at least in part on the discovery of therapeutic agents capable of preventing, inhibiting or modulating abnormal processing, misfolding or aggregation of protein. The therapeutic agents of the invention may prevent, inhibit or modulate the formation of inclusions. The therapeutic agents of the invention may ... 09/01/05 - 20050192282 - Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma where R1a, R1b, R2, R3, R4, R5, R6, R9, R10 and Y are as defined herein. ... 08/25/05 - 20050187221 - Method of treating ischemia reperfusion injury The invention provides a method of treating or preventing ischemia reperfusion injury in a subject in need thereof comprising administering a cytokine production inhibitor to a subject. ... 08/04/05 - 20050171115 - Alkanol and cycloalkanol-amine derivatives and methods of their use The present invention is directed to alkanoyl and cycloalkanoyl-amine derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, ... 07/28/05 - 20050165025 - Combination therapy with 5ht 1a and 5ht 1b-receptor antagonists Described is the novel use of combinations of molecules endowed with antagonistic activity toward the serotonin 5-HT1A or 5-HT1B receptor, and of molecules simultaneously endowed with antagonistic activity at both said receptors. These compounds and their enantiomers, diastereoisomers, N-oxides, polymorphs, solvates, prodrugs, and pharmaceutically acceptable salts are useful in the ... 07/07/05 - 20050148595 - Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use The present invention is directed to arylalkyl- and cycloalkylalkyl-piperazine derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, ... 07/07/05 - 20050148594 - Salts of fenofibric acid and pharmaceutical formulations thereof In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients. In ... 06/30/05 - 20050143385 - Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors wherein: Cy is independently a cyclyl group; Q1 is independently a covalent bond or cyclyl leader group; the piperazin-1,4-diyl group is optionally substituted; J1 is independently a covalent bond or —C(═;O)—; J2 is independently —C(═O)— or —S(═O)2—; Q2 is independently an acid leader group; wherein: Cy is independently: C3-20carbocyclyl, C3-20heterocyclyl, ... 06/23/05 - 20050137205 - Formulation for treating periocular disease A composition and method which combines, in one singular therapeutically effective application, antiinflammatory properties with cell proliferant and tissue repair qualities, together with cleansing properties for the periocular skin. The composition includes, in approximate parts by weight, Deionized water (20-80 by composition) Sodium Lauryl Sulfate in concentration of 0.3-20, Potassium ... ### FreshPatents.com Support |